Southfield Rehabilitation Company

Southfield Rehabilitation Company was paid $4.84M by Medicaid between Jan 2018 and Dec 2024, across 103 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 32% of everything it billed.

Compared with peers

Next to other Orthopaedic Hand Surgery Physician providers in Michigan

Rank by total paid#1 of 7

Median peer was paid$514K

This provider vs. median9.4×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	16,165	$1.69M
2019	12,822	$349K
2020	13,373	$852K
2021	19,373	$1.01M
2022	15,006	$492K
2023	9,174	$190K
2024incomplete	21,010	$260K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	32%	14,078	4,754	$1.55M
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	23%	10,989	9,624	$1.12M
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	11%	8,910	7,458	$515K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	8.2%	4,218	4,082	$396K
95910		4.2%	1,910	1,060	$203K
64721		2.6%	206	204	$126K
95908		2.5%	1,251	681	$121K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	1.7%	4,839	4,052	$80K
95886		1.4%	5,327	2,410	$70K
01810		1.2%	1,548	1,521	$57K
01830		<1%	1,188	1,180	$47K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	2,435	2,316	$40K

91 more codes

76000		<1%	1,566	$38K
64417		<1%	1,320	$33K
84443	Thyroid stimulating hormone (TSH)	<1%	2,859	$29K
80061	Lipid panel	<1%	3,330	$27K
80053	Comprehensive metabolic panel	<1%	4,256	$25K
73222		<1%	110	$24K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	1,455	$22K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	1,717	$20K
95909		<1%	201	$19K
26445		<1%	24	$18K
86803		<1%	2,158	$16K
73721	Magnetic resonance imaging, any joint of lower extremity; without contrast material	<1%	181	$16K
83036	Hemoglobin; glycosylated (A1C)	<1%	2,480	$14K
85027		<1%	3,493	$12K
64415		<1%	326	$12K
G0463	Hospital outpatient clinic visit for assessment and management of a patient	<1%	173	$11K
87340		<1%	2,038	$11K
86780		<1%	1,572	$10K
73115		<1%	92	$10K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	404	$9K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	403	$9K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	400	$8K
84439		<1%	1,489	$8K
84481		<1%	684	$7K
82607		<1%	803	$6K
86706		<1%	1,121	$6K
86704		<1%	968	$6K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	1,214	$6K
84153		<1%	481	$5K
86790		<1%	652	$5K
86705		<1%	748	$4K
80074		<1%	175	$4K
87481		<1%	191	$4K
87563		<1%	198	$4K
87511		<1%	185	$4K
73221		<1%	46	$3K
82746		<1%	357	$3K
87653		<1%	159	$3K
82728		<1%	376	$3K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	210	$3K
76942		<1%	1,905	$3K
20680		<1%	26	$3K
0001A		<1%	71	$2K
0002A		<1%	65	$2K
73218		<1%	24	$2K
87529		<1%	86	$2K
83550		<1%	347	$2K
25246		<1%	87	$2K
86696		<1%	168	$2K
36415	Collection of venous blood by venipuncture	<1%	2,105	$2K
83540		<1%	356	$1K
80048	Basic metabolic panel (calcium, ionized)	<1%	284	$1K
86695		<1%	168	$1K
73200		<1%	28	$1K
99213	Doctor's office visit, returning patient (routine)	<1%	50	$1K
84550		<1%	382	$1K
84460		<1%	416	$1K
88304		<1%	76	$971.66
84450		<1%	416	$912.54
76376		<1%	267	$904.80
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	76	$869.80
84403		<1%	47	$763.77
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	25	$735.74
84238		<1%	28	$612.65
86328		<1%	46	$553.13
86709		<1%	93	$549.33
95885		<1%	67	$517.72
83615		<1%	176	$517.42
83721		<1%	81	$494.59
86702		<1%	66	$419.71
83718		<1%	90	$357.05
86592		<1%	145	$335.27
82550		<1%	74	$305.88
84478		<1%	90	$253.44
82465		<1%	114	$250.98
84402		<1%	13	$221.79
86038		<1%	28	$221.65
85652		<1%	91	$149.07
85045		<1%	53	$144.44
86140		<1%	35	$110.22
83735		<1%	25	$106.95
86431		<1%	27	$99.55
82947		<1%	34	$86.49
84100		<1%	25	$72.44
81001		<1%	38	$71.41
87086	Culture, bacterial; quantitative colony count, urine	<1%	12	$61.18
84520		<1%	26	$60.65
82565		<1%	14	$45.47
80050	General health panel	0%	244	$0.00
C1713	Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	0%	157	$0.00
Q9966	Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml	0%	42	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSELEY, RONDA (PRESIDENT)

Same official

Other billing entities under SELEY, RONDA

Full network →

Provider	Location	Paid
Southfield Rehabilitation Company	Warren, MI	$83K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.